Another biotech shooting star coughs and splutters after a poor clinical trial. Meanwhile, PNG-focused Mayur Resources’ $15.5m IPO looks likely to close oversubscribed on the back of its multi-commodity strategy. Show More
minerals sands
Another biotech shooting star coughs and splutters after a poor clinical trial. Meanwhile, PNG-focused Mayur Resources’ $15.5m IPO looks likely to close oversubscribed on the back of its multi-commodity strategy. Show More